Krystal Biotech Stock Forecast, Price & News

Krystal Biotech (NASDAQ:KRYS) Frequently Asked Questions

Is Krystal Biotech a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Krystal Biotech stock.
View analyst ratings for Krystal Biotech or view top-rated stocks.

What stocks does MarketBeat like better than Krystal Biotech?

Wall Street analysts have given Krystal Biotech a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Krystal Biotech wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Krystal Biotech's next earnings date?

Krystal Biotech is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Krystal Biotech.

How were Krystal Biotech's earnings last quarter?

Krystal Biotech, Inc. (NASDAQ:KRYS) posted its earnings results on Sunday, August, 8th. The company reported ($0.74) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.76) by $0.02.
View Krystal Biotech's earnings history.

How has Krystal Biotech's stock price been impacted by Coronavirus?

Krystal Biotech's stock was trading at $49.92 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, KRYS shares have increased by 15.6% and is now trading at $57.72.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for KRYS?

6 equities research analysts have issued 1 year target prices for Krystal Biotech's stock. Their forecasts range from $90.00 to $103.00. On average, they expect Krystal Biotech's share price to reach $97.50 in the next year. This suggests a possible upside of 68.9% from the stock's current price.
View analysts' price targets for Krystal Biotech or view top-rated stocks among Wall Street analysts.

Who are Krystal Biotech's key executives?

Krystal Biotech's management team includes the following people:

• Krish S. Krishnan, Chairman, President & Chief Executive Officer
• Suma M. Krishnan, Chief Operating Officer & Director
• Trevor Parry, Director-IP & Scientific Affairs
• Brittani Agostini, Manager-Clinical Operations
• George Chen, Manager-Information Technology & CSV

Who are some of Krystal Biotech's key competitors?

Some companies that are related to Krystal Biotech include Adaptive Biotechnologies (ADPT), Adagio Therapeutics (ADGI), Abcam (ABCM), Recursion Pharmaceuticals (RXRX), Sana Biotechnology (SANA), Iovance Biotherapeutics (IOVA), Editas Medicine (EDIT), Ablynx (ABLYF), Allogene Therapeutics (ALLO), Relay Therapeutics (RLAY), Bavarian Nordic A/S (BVNRY), SpringWorks Therapeutics (SWTX), Kymera Therapeutics (KYMR), Instil Bio (TIL) and Ginkgo Bioworks (DNA).
View all of KRYS's competitors.

What other stocks do shareholders of Krystal Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Krystal Biotech investors own include Pfizer (PFE), Allena Pharmaceuticals (ALNA), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), VBI Vaccines (vbiv), Verastem (VSTM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT) and NVIDIA (NVDA).

When did Krystal Biotech IPO?

(KRYS) raised $30 million in an IPO on Wednesday, September 20th 2017. The company issued 3,000,000 shares at a price of $9.00-$11.00 per share. Ladenburg Thalmann served as the underwriter for the IPO.

What is Krystal Biotech's stock symbol?

Krystal Biotech trades on the NASDAQ under the ticker symbol "KRYS."

Who are Krystal Biotech's major shareholders?

Krystal Biotech's stock is owned by many different retail and institutional investors. Top institutional investors include Redmile Group LLC (9.33%), FMR LLC (7.96%), BlackRock Inc. (6.90%), Lord Abbett & CO. LLC (5.37%), Vanguard Group Inc. (3.81%) and Frazier Management LLC (3.55%). Company insiders that own Krystal Biotech stock include Krish S Krishnan and Suma Krishnan.
View institutional ownership trends for Krystal Biotech.

Which institutional investors are selling Krystal Biotech stock?

KRYS stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Frazier Management LLC, Goldman Sachs Group Inc., Credit Suisse AG, Mitsubishi UFJ Kokusai Asset Management Co. Ltd., Rafferty Asset Management LLC, Hood River Capital Management LLC, and Principal Financial Group Inc..
View insider buying and selling activity for Krystal Biotech or view top insider-selling stocks.

Which institutional investors are buying Krystal Biotech stock?

KRYS stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Point72 Asset Management L.P., Skandinaviska Enskilda Banken AB publ, Dimensional Fund Advisors LP, State Street Corp, BlackRock Inc., First Light Asset Management LLC, and Geode Capital Management LLC.
View insider buying and selling activity for Krystal Biotech or or view top insider-buying stocks.

How do I buy shares of Krystal Biotech?

Shares of KRYS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Krystal Biotech's stock price today?

One share of KRYS stock can currently be purchased for approximately $57.72.

How much money does Krystal Biotech make?

Krystal Biotech has a market capitalization of $1.28 billion. The company earns $-32,170,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis.

How many employees does Krystal Biotech have?

Krystal Biotech employs 75 workers across the globe.

What is Krystal Biotech's official website?

The official website for Krystal Biotech is www.krystalbio.com.

Where are Krystal Biotech's headquarters?

Krystal Biotech is headquartered at 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203.

How can I contact Krystal Biotech?

Krystal Biotech's mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The company can be reached via phone at (412) 586-5830 or via email at [email protected].